Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More
Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More
CADILA HEALTHCARE | IPCA LABS | CADILA HEALTHCARE/ IPCA LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 28.9 | 25.3 | 114.1% | View Chart |
P/BV | x | 4.6 | 7.9 | 58.9% | View Chart |
Dividend Yield | % | 0.7 | 0.2 | 483.5% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
CADILA HEALTHCARE Mar-20 |
IPCA LABS Mar-19 |
CADILA HEALTHCARE/ IPCA LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 352 | 1,042 | 33.8% | |
Low | Rs | 207 | 590 | 35.0% | |
Sales per share (Unadj.) | Rs | 139.2 | 298.6 | 46.6% | |
Earnings per share (Unadj.) | Rs | 11.8 | 35.0 | 33.6% | |
Cash flow per share (Unadj.) | Rs | 18.6 | 49.4 | 37.6% | |
Dividends per share (Unadj.) | Rs | 3.50 | 3.00 | 116.7% | |
Dividend yield (eoy) | % | 1.3 | 0.4 | 340.8% | |
Book value per share (Unadj.) | Rs | 101.4 | 247.1 | 41.0% | |
Shares outstanding (eoy) | m | 1,023.74 | 126.35 | 810.2% | |
Bonus/Rights/Conversions | - | ESOS | - | ||
Price / Sales ratio | x | 2.0 | 2.7 | 73.4% | |
Avg P/E ratio | x | 23.7 | 23.3 | 101.9% | |
P/CF ratio (eoy) | x | 15.0 | 16.5 | 91.2% | |
Price / Book Value ratio | x | 2.8 | 3.3 | 83.5% | |
Dividend payout | % | 29.8 | 8.6 | 347.1% | |
Avg Mkt Cap | Rs m | 286,033 | 103,108 | 277.4% | |
No. of employees | `000 | 13.4 | 13.4 | 99.7% | |
Total wages/salary | Rs m | 24,145 | 7,874 | 306.6% | |
Avg. sales/employee | Rs Th | 10,632.7 | 2,807.0 | 378.8% | |
Avg. wages/employee | Rs Th | 1,801.2 | 585.8 | 307.5% | |
Avg. net profit/employee | Rs Th | 898.5 | 329.0 | 273.1% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 142,531 | 37,732 | 377.7% | |
Other income | Rs m | 1,139 | 577 | 197.5% | |
Total revenues | Rs m | 143,670 | 38,309 | 375.0% | |
Gross profit | Rs m | 24,198 | 6,901 | 350.7% | |
Depreciation | Rs m | 6,965 | 1,824 | 381.8% | |
Interest | Rs m | 3,418 | 189 | 1,811.3% | |
Profit before tax | Rs m | 14,954 | 5,465 | 273.7% | |
Minority Interest | Rs m | 288 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 3,198 | 1,042 | 306.8% | |
Profit after tax | Rs m | 12,044 | 4,422 | 272.4% | |
Gross profit margin | % | 17.0 | 18.3 | 92.8% | |
Effective tax rate | % | 21.4 | 19.1 | 112.1% | |
Net profit margin | % | 8.5 | 11.7 | 72.1% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 87,154 | 23,778 | 366.5% | |
Current liabilities | Rs m | 82,694 | 10,975 | 753.5% | |
Net working cap to sales | % | 3.1 | 33.9 | 9.2% | |
Current ratio | x | 1.1 | 2.2 | 48.6% | |
Inventory Days | Days | 71 | 104 | 68.8% | |
Debtors Days | Days | 94 | 66 | 142.3% | |
Net fixed assets | Rs m | 133,236 | 20,368 | 654.2% | |
Share capital | Rs m | 1,024 | 253 | 405.2% | |
"Free" reserves | Rs m | 102,733 | 30,971 | 331.7% | |
Net worth | Rs m | 103,757 | 31,224 | 332.3% | |
Long term debt | Rs m | 32,146 | 1,409 | 2,282.3% | |
Total assets | Rs m | 236,866 | 45,507 | 520.5% | |
Interest coverage | x | 5.4 | 30.0 | 17.9% | |
Debt to equity ratio | x | 0.3 | 0 | 686.8% | |
Sales to assets ratio | x | 0.6 | 0.8 | 72.6% | |
Return on assets | % | 6.5 | 10.1 | 64.4% | |
Return on equity | % | 11.6 | 14.2 | 82.0% | |
Return on capital | % | 13.7 | 17.3 | 79.3% | |
Exports to sales | % | 0 | 45.9 | 0.0% | |
Imports to sales | % | 0 | 16.6 | 0.0% | |
Exports (fob) | Rs m | NA | 17,308 | 0.0% | |
Imports (cif) | Rs m | NA | 6,266 | 0.0% | |
Fx inflow | Rs m | 52,752 | 17,308 | 304.8% | |
Fx outflow | Rs m | 14,504 | 6,266 | 231.5% | |
Net fx | Rs m | 38,248 | 11,042 | 346.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 25,054 | 4,923 | 508.9% | |
From Investments | Rs m | -10,123 | -1,563 | 647.6% | |
From Financial Activity | Rs m | -10,942 | -1,832 | 597.3% | |
Net Cashflow | Rs m | 3,989 | 1,528 | 261.1% |
Indian Promoters | % | 74.8 | 45.9 | 163.0% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 8.3 | 11.4 | 72.8% | |
FIIs | % | 5.9 | 25.3 | 23.3% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 11.0 | 17.4 | 63.2% | |
Shareholders | 44,069 | 36,892 | 119.5% | ||
Pledged promoter(s) holding | % | 0.0 | 2.1 | - |
Compare CADILA HEALTHCARE With: ORCHID PHARMA CIPLA ASTRAZENECA PHARMA AUROBINDO PHARMA STERLING BIOTECH
Compare CADILA HEALTHCARE With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Asian share markets are trading on a mixed note today. All eyes are on the US Federal Reserve policy outcome due later today.
Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.
For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.
For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.
More Views on NewsIn this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
The pandemic failed to thwart Richa's investing success formula for 2020.
In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.
Our ace stock picker is ready to capitalise on a big growth opportunity.
More